| Literature DB >> 22953730 |
Claudia M Witt1, Mikel Aickin, Trini Baca, Dan Cherkin, Mary N Haan, Richard Hammerschlag, Jason Jishun Hao, George A Kaplan, Lixing Lao, Terri McKay, Beverly Pierce, David Riley, Cheryl Ritenbaugh, Kevin Thorpe, Sean Tunis, Jed Weissberg, Brian M Berman.
Abstract
BACKGROUND: There is a need for more Comparative Effectiveness Research (CER) to strengthen the evidence base for clinical and policy decision-making. Effectiveness Guidance Documents (EGD) are targeted to clinical researchers. The aim of this EGD is to provide specific recommendations for the design of prospective acupuncture studies to support optimal use of resources for generating evidence that will inform stakeholder decision-making.Entities:
Mesh:
Year: 2012 PMID: 22953730 PMCID: PMC3495216 DOI: 10.1186/1472-6882-12-148
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Checklist for CER relevant aspects for acupuncture clinical studies
| Stakeholder involvement | □ All relevant stakeholders are involved in |
| □ Identification of research topic | |
| □ Plan and design of CER | |
| □ Interpretation of results | |
| Efficacy-effectiveness continuum | □ Study location on the efficacy-effectiveness continuum is determined for participant selection/eligibility criteria, treatment protocol, practitioner expertise, outcomes, setting in which the study is conducted. |
| Eligibility criteria | □ Study population reflects those who usually receive this treatment |
| □ Study population includes both acupuncture- naïve and acupuncture-non-naïve patients | |
| Patient recruitment | □ Patients are recruited from site where the treatment is usually employed |
| Acupuncture intervention | □ Adequate consensus procedure is used to define intervention |
| Comparison groups | □ Adequate consensus procedure used to define comparison(s) |
| □ Definitions and details for terms such as “usual care” provided | |
| Treatment documentation | □ Documentation reflects which treatments were received in all groups (interventions and co-interventions) |
| Measures | □ Widely accepted or standardized outcome measure used |
| □ Secondary outcomes capture relevant patient-centered dimensions for the condition under study | |
| Timing | □ Assessment schedule is balanced gaining study relevant data without substantially disrupting treatment protocol or setting |
| Allocation | □ Allocation is concealed |
| □ Stratification for subgroups or dynamic allocation for key characteristics used | |
| Blinding | □ Outcome data inaccessible to practitioners |
| □ Blinded outcome rater, if possible, used | |
| Preferences/ expectation | □ Preferences and expectations measured at baseline |
| Sample size | □ Sample size takes patient heterogeneity into account |
| □ Required sample size is feasible | |
| □ Study has enough power for planned subgroup analyses | |
| Subgroups | □ Relevant subgroups preplanned (e.g. gender) |
| □ Exploratory subgroup analysis mentioned in study aims | |
| Statistical analysis | □ Intention-to-treat analyses planned |
| □ Relevant subgroup analyses planned | |
| □ Adjusted for stratification variables, baseline differences and relevant confounders | |
| | □ Setting reflects reality in clinical practice |
| Methodological approach | □ Standard methods for economic evaluations used |
| □ Sensitivity analysis for all relevant stakeholder perspectives | |
| □ Relevant subgroups identified | |
| Observation time | □ In chronic diseases long-term observation (≥ 12 months), if possible, planned |
| Guidelines | □ Relevant guidelines (e.g. CONSORT) consulted and followed |
| Content | □ Stated how and why this is CER |
| □ Study setting (incl. procedure of practitioner selection) described in detail | |
| □ Treatment group description from informed consent provided | |
| □ Comparison groups described in detail | |
| □ Data provided on all interventions and co-interventions received | |
| □ Relevant subgroup analyses reported | |